ACADIA Pharmaceuticals Inc (FRA:DR6)
€ 13.295 -0.225 (-1.66%) Market Cap: 2.29 Bil Enterprise Value: 1.88 Bil PE Ratio: 83.33 PB Ratio: 4.82 GF Score: 73/100

ACADIA Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 01, 2021 / 05:20PM GMT
Release Date Price: €40.77 (+3.39%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Hi, everyone. Thanks for joining us at the Cowen Healthcare Conference. A fireside chat with ACADIA Pharmaceuticals. I'm covering analyst Ritu Baral. And with us from ACADIA, we have CEO, Steve Davis; CFO, Elena Ridloff; and President, Serge Stankovic. Thanks, everyone, Steve. Thank you. I will let you, Steve kick it off with just a couple of minutes of level setting where you guys are right now before we dive into questions.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

That sounds great. Thanks much, Ritu. I'd like to start just with a few highlights, again, as you say, to level set.

First, we're driving NUPLAZID growth in PDP. In 2020, we achieved net sales of $441.8 million, representing 30% year-over-year growth. We continue to add new prescribers and new patients and see high adherence among our continuing PDP patients. Based on our 2020 performance and current outlook, we expect 2021 net sales in PDP, again, I just want

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot